Your submission is now in Draft mode.

Once it's ready, please submit your draft for review by our team of Community Moderators. Thank you!

Submit Essay

Once you submit your essay, you can no longer edit it.

Pending

This content now needs to be approved by community moderators.

Submitted

This essay was submitted and is waiting for review.

Nanoparticle Cancer Therapy Approved by 2031

Question

This question supports and is linked to a fortified essay on the future of nanotechnology by Physical Chemist Kevin Ausman. Click here to read the full essay. There is a related question, whether nanoparticle-enabled cancer therapy will be approved by 2041, here.

Inorganic nanoparticles are small collections of a few thousand to a few billion atoms, typically ranging from 1 to 100 nm in diameter. They have many peculiar chemical and physical properties, which make them attractive for designing therapies.

An example of such technology is called Aurolase Therapy, and has been in development for two decades. It's now in pilot studies in humans with early results giving reason for optimism.

Will an inorganic nanoparticle-enabled cancer therapy be approved by the FDA before 2031?

This question will resolve as Yes if, before January 1, 2031, the FDA gives full approval to a cancer therapy that uses inorganic nanoparticles in the patient's treatment. The therapy must target the cancer cells rather than downstream symptoms. We specify "inorganic" to exclude lipid nanoparticles etc.

Make a Prediction

Prediction

Note: this question resolved before its original close time. All of your predictions came after the resolution, so you did not gain (or lose) any points for it.

Note: this question resolved before its original close time. You earned points up until the question resolution, but not afterwards.

Current points depend on your prediction, the community's prediction, and the result. Your total earned points are averaged over the lifetime of the question, so predict early to get as many points as possible! See the FAQ.